teaser
Two European drug firms are to collaborate on developing a promisingoncology compound. The UK’s Vernalis and France’s Servier will useVernalis’s proprietary drug discovery platform on an undisclosedtarget.
Vernalis chief executive Simon Sturge said thecollaboration with Servier followed on from a recent announcement thatanother of its partners, Novartis, had selected a second compound thatinhibits Hsp90, a target for a number of different cancer indications.
PharmaTimes 17/5/2007
